Proteomics Study of Mesenchymal Stem Cell-Like Cells Obtained from Tumor Microenvironment of Patients with Malignant and Benign Salivary Gland Tumors

(Pages: 196-203)
Mohammad Reza Haghshenas, Ph.D, 1Nasrollah Erfani, Ph.D, 1,2Soolmaz Khansalar, M.Sc, 1Bijan Khademi, M.D, 3Mohammad Javad Ashraf, M.D., 4Mahboobeh Razmkhah, Ph.D., 1,*Abbas Ghaderi, Ph.D., 1,2,*
Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Otolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Pathology, Khalili Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Otolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Pathology, Khalili Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
*Corresponding Address: P.O.Box: 71345-3119 Shiraz Institute for Cancer Research School of Medicine Shiraz University of Medical Sciences Shiraz Iran Emails:razmkhahm@sums.ac.ir,ghaderia@sums.ac.ir
Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0) License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Haghshenas Mohammad Reza, Erfani Nasrollah, Khansalar Soolmaz, Khademi Bijan, Ashraf Mohammad Javad, Razmkhah Mahboobeh, Ghaderi Abbas. Proteomics Study of Mesenchymal Stem Cell-Like Cells Obtained from Tumor Microenvironment of Patients with Malignant and Benign Salivary Gland Tumors. Cell J. 2022; 24(4): 196-203.

Abstract

Objective

Salivary gland tumors (SGTs) show some aggressive and peculiar clinicopathological behaviors that might be related to the components of the tumor microenvironment, especially mesenchymal stem cells (MSCs)-associated proteins. However, the role of MSCs-related proteins in SGTs tumorigenesis is poorly understood. This study aimed to isolate and characterize MSCs from malignant and benign tumor tissues and to identify differentially expressed proteins between these two types of MSCs.

Materials and Methods

In this experimental study, MSC-like cells derived from benign (pleomorphic adenoma, n=5) and malignant (mucoepidermoid carcinoma, n=5) tumor tissues were verified by fluorochrome antibodies and flow cytometric analysis. Differentially expressed proteins were identified using two-dimensional polyacrylamide gel electrophoresis (2DE) and Mass spectrometry.

Results

Results showed that isolated cells strongly expressed characteristic MSCs markers such as CD44, CD73, CD90, CD105, and CD166, but they did not express or weakly expressed CD14, CD34, CD45 markers. Furthermore, the expression of CD24 and CD133 was absent or near absent in both isolated cells. Results also discovered overexpression of Annexin A4 (Anxa4), elongation factor 1-delta (EF1-D), FK506 binding protein 9 (FKBP9), cytosolic platelet-activating factor acetylhydrolase type IB subunit beta (PAFAH1B), type II transglutaminase (TG2), and s-formylglutathione hydrolase (FGH) in MSCs isolated from the malignant tissues. Additionally, heat shock protein 70 (Hsp70), as well as keratin, type II cytoskeletal 7 (CK-7), were found to be overexpressed in MSCs derived from the benign ones.

Conclusion

Malignant and benign SGTs probably exhibit a distinct pattern of tissue proteins that are most likely related to the metabolic pathway. However, further studies in a large number of patients are required to determine the applicability of identified proteins as new targets for cancer therapy.